Chief Business Officer
Jim Connolly joined Adjuvance Technologies in April 2020. He is the former president and CEO of Aeras, a nonprofit organization dedicated to developing tuberculosis vaccines. He served in this role from 2010 through 2012 and as Aeras board member until the asset transfer to IAVI in 2018. Recently, Connolly served as CEO of Tivorsan Pharmaceuticals and as consultant/adviser to various pharmaceutical, biotech, and investment organizations. Connolly joined Aeras after over 23 years of pharmaceutical industry experience at Wyeth (now Pfizer), where he held a series of increasingly senior management, commercial, business development, and finance positions, including Executive Vice President and General Manager, Wyeth Vaccines and President and Managing Director, Wyeth Canada. During his tenure leading Wyeth Vaccines from 2005 to 2009, Connolly played a leading role in building the company’s vaccines business into one of the top four global manufacturers and expanding access to the breakthrough pneumococcal vaccine Prevnar to more than 100 countries and 35 national immunization programs, including numerous emerging and developing countries where pneumococcal disease is a major cause of child mortality. Currently, he is on the board of directors of IAVI, Ambulatus Robotics and Covenant House Pennsylvania.